Novacyt S.A. Notice of Results (2157M)
13 Setembro 2023 - 3:00AM
UK Regulatory
TIDMNCYT
RNS Number : 2157M
Novacyt S.A.
13 September 2023
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Notice of Half Year 2023 Results and Investor Presentation
Paris, France and Eastleigh, UK - 13 September 2023 - Novacyt
S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international
specialist in clinical diagnostics, announces that it will report
its unaudited financial results for the six months ended 30 June
2023 on Thursday, 28 September 2023.
Investor webinar
An investor webinar presentation by James McCarthy, Acting Chief
Executive Officer, Steve Gibson, Group Finance Director and Lyn
Rees, Executive Director and former CEO of Yourgene , covering the
H1 2023 results will take place at 12.30pm BST on Thursday, 28
September 2023.
The webinar is open to all existing and potential investors, and
will consist of a presentation followed by a Q&A session, held
on the Investor Meet Company platform. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9.00am
the day before the meeting or at any time during the live
presentation. Automated French subtitling will be available
throughout the presentation.
Investors can sign up for the webinar via:
https://www.investormeetcompany.com/novacyt-sa/register-investor
Investors who already follow NOVACYT S.A. on the Investor Meet
Company platform will automatically be invited.
Contacts
Novacyt SA +44 (0)23 8074 8830
James Wakefield, Non-Executive
Chairman
James McCarthy, Acting Chief Executive
Officer
SP Angel Corporate Finance LLP (Nominated
Adviser and Broker) +44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Numis (Joint Broker) +44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Jack
McLaren
Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780
Stephanie Cuthbert / Anna Dunphy novacyt@walbrookpr.com
/ Phillip Marriage
About Novacyt Group
Novacyt is an international diagnostics business delivering a
broad portfolio of in vitro and molecular diagnostic tests for a
wide range of infectious diseases, enabling faster, more accurate,
accessible testing to improve healthcare outcomes. The Company
provides customers with a seamless sample-to-result workflow using
its integrated and scalable instrumentation/solutions. The Company
specialises in the design, manufacture, and supply of real-time PCR
kits, reagents and a full range of laboratory and qPCR
instrumentation for molecular biology research and clinical use.
Novacyt offers one of the world's most varied and comprehensive
range of qPCR assays, covering human, veterinary, biodefence,
environmental, agriculture and food testing.
The acquisition of Yourgene in September 2023 added a
complementary international genomics technology and services
business, focussed on delivering accurate molecular diagnostic and
screening solutions, across reproductive health and precision
medicine. Yourgene's portfolio of in vitro diagnostic products
includes non-invasive prenatal tests (NIPT) for Down's Syndrome and
other genetic disorders, Cystic Fibrosis screening tests, invasive
rapid aneuploidy tests and DPYD genotyping assays. Yourgene also
works in partnership with global leaders in DNA technology to allow
its Ranger(R) Technology to deliver dynamic target enrichment.
Novacyt is headquartered in Vélizy in France with offices in the
UK in Stokesley, Eastleigh and Manchester. The Company also has
offices in Taipei (divestment pending), Singapore, the US and
Canada and is listed on the London Stock Exchange's AIM market
("NCYT") and on the Paris Stock Exchange Euronext Growth
("ALNOV").
For more information, please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOREAKNAFENDEFA
(END) Dow Jones Newswires
September 13, 2023 02:00 ET (06:00 GMT)
Novacyt (LSE:NCYT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Novacyt (LSE:NCYT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024